# US 2024/0174762 A1 · Methods, compositions and uses for targeting sema7a in the diagnosis and treatment of health conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174762 A1
- Document ID: US20240174762A1
- Status: Published application
- Kind: A1
- Application number: 18/525,459
- Filed: 2023-11-30
- Published: 2024-05-30
- Earliest claimed: 2021-06-01
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, A Body Corporate
- Inventors: Traci R. LYONS; Robert HODGES
- Web page: https://patentgrep.com/patent/US20240174762A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 35/00: Antineoplastic agents
- C07K 14/4703: {Inhibitors; Suppressors}
- C07K 14/4705: {stimulating, promoting or activating activity}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/77: Internalization into the cell
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Embodiments of the present invention generally relate to compositions and methods for targeting Semaphorin 7a (SEMA7A) in health conditions. In certain embodiments, compositions and methods disclosed herein concern using SEMA7A targeting for diagnosis and treatment of cancers, cardiac conditions, and other health conditions. In some embodiments, SEMA7A peptide fragments and fusion polypeptides can be used to generate antibodies of use to diagnose, reduce metastasis and treat conditions disclosed herein. In certain embodiments, SEMA7A levels can be determined to project progression of a condition. In some embodiments, cancers can be targeted. In other embodiments, cancer stem cells can be targeted. In certain embodiments, SEMA7A levels can be assessed in breast cancers. In other embodiments, monoclonal antibodies against SEMA7A polypeptides can be used to treat cancers such as breast cancer and other cancers having aberrant SEMA7A expression in a subject.

## Claims

### Claim 1

A synthetic molecule comprising, an isolated or synthetic polypeptide comprising at least 75% homology to the polypeptide represented by SEQ. ID. NO:2, wherein the isolated or synthetic polypeptide fragment comprising at least 75% homology to the polypeptide represented by SEQ. ID. NO:2 is not part of a full-length naturally occurring Semaphorin 7a (SEMA7A) molecule.

### Claim 2 (depends on 1)

The synthetic molecule according to claim 1, wherein the isolated or synthetic polypeptide is fused to a second molecule for formation of a fusion polypeptide.

### Claim 3 (depends on 2)

The synthetic molecule according to claim 2, wherein the second molecule comprises an antibody fragment, an immunogen, a peptide transduction domain, or a conjugate.

### Claim at position 4

4-6. (canceled)

### Claim 7 (depends on 1)

An antibody or antibody fragment thereof against the isolated or synthetic polypeptide according to claim 1, wherein the antibody or antibody fragment thereof is capable of binding an isolated or synthetic polypeptide according to claim 1 and capable of at least one of inhibiting expression of SEMA7A, inhibiting activity of SEMA7A, and killing cells expressing SEMA7A.

### Claim 8 (depends on 7)

The antibody according to claim 7, wherein the antibody comprises a monoclonal antibody or a polyclonal antibody.

### Claim 9

(canceled)

### Claim 10 (depends on 7)

A pharmaceutical composition comprising the antibody according to claim 7, and a pharmaceutically acceptable excipient.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, further comprising one or more anti-cancer agents or immunostimulatory agents.

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the one or more anti-cancer agents or immunostimulatory agents comprise one or more of an anti-BCL-2, anti-PD-L1, or anti-PD-1 antibody.

### Claim 13

(canceled)

### Claim 14 (depends on 10)

The pharmaceutical composition according to claim 10, wherein pharmaceutical composition further comprises an anti-estrogen therapeutic, an estrogen receptor antagonist, or other endocrine modulating therapeutic.

### Claim at position 13

15-16. (canceled)

### Claim 17 (depends on 1)

A polynucleotide encoding the polypeptide according to claim 1.

### Claim 18 (depends on 17)

The polynucleotide according to claim 17, further comprising a vector for expressing the encoded polypeptide.

### Claim 19 (depends on 17)

A host cell comprising the polynucleotide according to claim 17.

### Claim 20 (depends on 10)

A method for treating a subject having a health condition with elevated SEMA7A expression, comprising administering to the subject having the health condition, a pharmaceutical composition according to claim 10 and treating the health condition.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the health condition comprises cancer.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The method according to claim 21, wherein the cancer comprises breast cancer.

### Claim 24

(canceled)

### Claim 25 (depends on 23)

The method according to claim 23, wherein the breast cancer comprises estrogen receptor positive or estrogen receptor negative breast cancer (ER+BC, ER−BC) or postpartum breast cancer (PPBC).

### Claim 26

(canceled)

### Claim 27 (depends on 20)

The method according to claim 20, wherein administering at least one additional therapeutic composition to the subject comprises administering one or more cell survival pathway inhibitor-containing composition, wherein the at least one additional therapeutic composition does not include an anti-estrogen-based therapy, does not include an anti-CDK4/6 therapy or does not include chemotherapy.

### Claim 28

(canceled)

### Claim 29

A method for predicting breast cancer relapse in a subject comprising obtaining at least one sample from a subject having breast cancer and analyzing the at least one sample for SEMA7A presence and/or concentration and predicting breast cancer relapse in the subject based on presence and/or concentration of SEMA7A.

### Claim at position 27

30-32. (canceled)

### Claim 33 (depends on 10)

A kit comprising the pharmaceutical composition according to claim 10; and at least one container.

### Claim 34

A method for diagnosing risk for and prognosis of a health condition comprising, obtaining one or more blood samples from a subject, measuring concentration of SEMA7A in the blood sample, and treating the subject according to the level of SEMA7A in the blood sample.

### Claim at position 30

35-36. (canceled)

### Claim 37 (depends on 34)

The method according to claim 34, wherein the concentration of SEMA7A in the one or more blood sample indicative of the need for therapeutic intervention comprises about 0.1 ng/ml, or about 0.5 ng/ml to about 1.5 ng/ml or more.

### Claim 38 (depends on 10)

A method for reducing the risk of onset or treating cancer in a subject expressing or having elevated concentrations of SEMA7A comprising administering a pharmaceutical composition according to claim 10 to the subject.

### Claim 39

A method for reducing or eliminating at least one of cancer stem cells, cancer stem cell activities and cancer cell metastasis comprising, treating a subject having cancer with a pharmaceutical composition capable of inhibiting at least one of SEMA7A expression and SEMA7A activity; and reducing or eliminating at least one of cancer stem cells, cancer stem cell activities and cancer cell metastasis.

### Claim at position 34

40-42. (canceled)
